Journal
LIFE-BASEL
Volume 13, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/life13020486
Keywords
idiopathic pulmonary fibrosis (IPF); treatment; pharmacotherapy; anti-fibrotic; novel; adjunct; pathophysiology; etiology
Categories
Ask authors/readers for more resources
This review article summarizes the existing and novel pharmacotherapies for the treatment of idiopathic pulmonary fibrosis (IPF), focusing on the current knowledge on the pathophysiology of the disease, mechanism of action of the drugs, and clinical trials.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrosing interstitial lung disease that occurs predominantly in the older population. There is increasing incidence and prevalence in IPF globally. The emergence of anti-fibrotic therapies in the last decade have improved patient survival though a cure is yet to be developed. In this review article, we aim to summarize the existing and novel pharmacotherapies for the treatment of IPF (excluding treatments for acute exacerbations), focusing on the current knowledge on the pathophysiology of the disease, mechanism of action of the drugs, and clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available